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Background
Designing immunogens that will elicit neutralizing anti-
bodies (NAbs) directed at the CD4 receptor binding site
(CD4-BS) of the HIV-1 envelope remains a major priority
for vaccine research. Little is known about broadly reac-
tive anti-CD4-BS NAb responses and the development of
resistance to these antibodies in the natural infection set-
ting. We previously described an HIV+ subject, VC10042,
whose exceptionally broad cross-neutralizing activity was
due to NAbs targeting the CD4-BS. These anti-CD4-BS
antibodies potently neutralize diverse HIV-1 isolates, irre-
spective of clade. Here we investigated the autologous
neutralizing response of VC10042 and characterized cir-
culating autologous viral strains, providing an opportu-
nity to study potential mechanisms of escape from cross-
reactive anti-CD4-BS NAbs during natural infection.
Methods
Autologous envelope (Env) sequences were amplified
from plasma virus and were multiply aligned for compar-
ison to reference sequences. Variable resides in the CD4
binding site and the mAb b12 epitope were mapped onto
the gp120 crystal structure. Autologous Envs were pseudo-
typed and tested for co-receptor usage, sensitivity to
known neutralizing antibodies, and sensitivity to autolo-
gous plasma.
Results
All Env clones efficiently utilized the CCR5 and, to a lesser
extent, the CXCR4 co-receptors, while only a few clones
could enter target cells in a CD4-independent manner. All
clones were completely resistant to MAb b12, but were
sensitive (to varying degrees) to the autologous anti-CD4-
BS NAbs. Resistance to b12 was mapped to the simultane-
ous presence of 2 amino acids: R373 (C3) and N386 (C4).
Conclusion
Our results indicate HIV-1 can escape the action of the
broadly neutralizing MAb b12 but still remain susceptible
to naturally developed anti-CD4-BS NAbs and utilize the
CD4 molecule for entry. Defining the precise epitopes rec-
ognized by these broadly neutralizing anti-CD4-BS anti-
bodies may lead to the development of immunogens
capable of eliciting similar anti-CD4-BS antibodies that
target the CD4-BS differently than MAb b12.
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